Published in Vaccines (Basel) on May 04, 2016
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2001) 9.19
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med (2001) 5.06
The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity (2008) 3.50
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol (1998) 2.93
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev (2009) 2.54
Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol (2001) 2.49
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine (2010) 1.88
Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev (2004) 1.77
The role of CpG motifs in innate immunity. Curr Opin Immunol (2000) 1.74
Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One (2009) 1.45
DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci U S A (2012) 1.29
Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev (1993) 1.19
Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol (2000) 1.17
IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine (2006) 1.15
CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA. Eur J Immunol (2006) 1.15
Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur Biophys J (2011) 1.12
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol (2006) 1.11
Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS One (2008) 1.08
CpG DNA: trigger of sepsis, mediator of protection, or both? Scand J Infect Dis (2003) 1.07
The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol (2000) 1.06
CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol (2001) 1.06
The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine (2004) 1.03
Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology (2002) 1.03
A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine (2009) 0.98
The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine (2008) 0.96
LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J Immunol (2009) 0.96
Activation of human neutrophils by a synthetic anti-microbial peptide, KLKLLLLLKLK-NH2, via cell surface calreticulin. Eur J Biochem (1999) 0.95
Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur J Immunol (2008) 0.95
Activation of human monocyte cell line U937 via cell surface calreticulin. Cell Stress Chaperones (2001) 0.93
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine (2015) 0.92
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol (2009) 0.90
The immunostimulatory activity of phosphorothioate CpG oligonucleotides is affected by distal sequence changes. Mol Immunol (2011) 0.90
Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells. Vaccine (2010) 0.88
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine (2015) 0.88
The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes. J Immunol (2010) 0.88
IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand J Immunol (2009) 0.86
Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine (2012) 0.85
Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep (2011) 0.85
Single molecule in vivo analysis of toll-like receptor 9 and CpG DNA interaction. PLoS One (2011) 0.84
Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation. Antisense Nucleic Acid Drug Dev (1997) 0.82
Synthetic innate defence regulator peptide enhances in vivo immunostimulatory effects of CpG-ODN in newborn piglets. Vaccine (2010) 0.80
CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses. Biomed Res Int (2013) 0.79
Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells. Clin Vaccine Immunol (2015) 0.77